Market Overview

UPDATE: Coronado Biosciences Presents Interim Data from Autism Study at Neuropsychopharmacology Meeting

Coronado Biosciences (Nasdaq: CNDO) today announced that Dr. Eric Hollander, Clinical Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine of Yeshiva University and Director of the Autism and Obsessive Compulsive Spectrum Program at Montefiore Medical Center and Einstein, presented interim data from his pilot study of oral TSO (Trichuris suis ova or CNDO-201) to treat autism at the American College of Neuropsychopharmacology Annual Meeting in Hollywood, Florida.

The study is a double-blind, randomized, placebo-controlled, cross-over study and enrolled 10 high-functioning adult autism spectrum disorder patients who were able to give informed consent to participate in the study and who had a history of allergies and/or a family history of immune-inflammatory illness. They were treated for 12 weeks with either TSO or placebo, followed by a 4-week washout phase and then 12 weeks of placebo or TSO. The TSO dosage used in the study was 2,500 ova once every two weeks.

In the first 5

See full press release

Posted-In: News Guidance Dividends Contracts FDA Legal Management Global

 

Most Popular

Related Articles (CNDO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free